| Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up M Ekstedt, H Hagström, P Nasr, M Fredrikson, P Stål, S Kechagias, ... Hepatology 61 (5), 1547-1554, 2015 | 2192 | 2015 |
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ... Hepatology 65 (5), 1557-1565, 2017 | 1644 | 2017 |
| Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Journal of hepatology 67 (6), 1265-1273, 2017 | 918 | 2017 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 716 | 2020 |
| Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis G Musso, R Gambino, JH Tabibian, M Ekstedt, S Kechagias, ... PLoS medicine 11 (7), e1001680, 2014 | 704 | 2014 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 427 | 2022 |
| Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort TG Simon, B Roelstraete, H Khalili, H Hagström, JF Ludvigsson Gut 70 (7), 1375-1382, 2021 | 366 | 2021 |
| Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ... Hepatology communications 2 (1), 48-57, 2018 | 254 | 2018 |
| Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study GJ Webb, T Marjot, JA Cook, C Aloman, MJ Armstrong, EJ Brenner, ... The lancet Gastroenterology & hepatology 5 (11), 1008-1016, 2020 | 250 | 2020 |
| FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 T Brevini, M Maes, GJ Webb, BV John, CD Fuchs, G Buescher, L Wang, ... Nature 615 (7950), 134-142, 2023 | 149 | 2023 |
| Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease H Hagström, M Talbäck, A Andreasson, G Walldius, N Hammar Gastroenterology 158 (1), 200-214, 2020 | 138 | 2020 |
| Adaptation of the Charlson comorbidity index for register-based research in Sweden JF Ludvigsson, P Appelros, J Askling, L Byberg, JJ Carrero, AM Ekström, ... Clinical epidemiology, 21-41, 2021 | 131 | 2021 |
| Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort TG Simon, B Roelstraete, H Hagström, J Sundström, JF Ludvigsson Gut 71 (9), 1867-1875, 2022 | 129 | 2022 |
| Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet–a randomised controlled trial M Holmer, C Lindqvist, S Petersson, J Moshtaghi-Svensson, V Tillander, ... JHEP Reports 3 (3), 100256, 2021 | 124 | 2021 |
| Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease H Hagström, M Talbäck, A Andreasson, G Walldius, N Hammar Journal of hepatology 73 (5), 1023-1029, 2020 | 123 | 2020 |
| Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population TG Simon, AS Duberg, S Aleman, H Hagstrom, LH Nguyen, H Khalili, ... Annals of internal medicine 171 (5), 318-327, 2019 | 117 | 2019 |
| Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement H Hagström, LA Adams, AM Allen, CD Byrne, Y Chang, H Grønbæk, ... Hepatology 74 (1), 474-482, 2021 | 113 | 2021 |
| Cancer risk in patients with biopsy‐confirmed nonalcoholic fatty liver disease: a population‐based cohort study TG Simon, B Roelstraete, R Sharma, H Khalili, H Hagström, ... Hepatology 74 (5), 2410-2423, 2021 | 109 | 2021 |
| Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis C Efe, H Hagström, H Ytting, RA Bhanji, NF Müller, Q Wang, T Purnak, ... Clinical Gastroenterology and Hepatology 15 (12), 1950-1956. e1, 2017 | 106 | 2017 |
| Adverse outcomes of pregnancy in women with non‐alcoholic fatty liver disease H Hagström, J Höijer, JF Ludvigsson, M Bottai, A Ekbom, R Hultcrantz, ... Liver International 36 (2), 268-274, 2016 | 100 | 2016 |
Per StålDocent i gastroenterologi, Karolinska InstitutetVerified email at ki.se
